glp 1 and heart failure Effects of Glucagon-Like Peptide Receptor Agonist Initiation in Patients With With Reduced Ejection Fraction Implantable Cardiac Devices Treatment of High-Risk Patients with

MeissnerWGRemyPGiordanaCMalteteDDerkinderenPHouetoJLet al

Medical supervision is essential for monitoring potential interactions with hormonal treatments and assessing ongoing effectiveness

Hernndez-Saavedra D, Hinkley JM, Baer LA, Pinckard KM, Vidal P, Nirengi S, et al

A press release from the phase 3 trial data for mazdutide (6 mg weekly for 48 weeks) showed a 14.8% WL (vs

Adjusted BMI thresholds for different ethnic backgrounds One of the most important but least discussed aspects of BMI and GLP-1 eligibility involves ethnic and racial differences in how BMI correlates with metabolic risk

Slower dose titration or temporary dose reduction may be appropriate if symptoms are severe